Status:
COMPLETED
Transfusion Treatment in Patients With SCD
Lead Sponsor:
Società Italiana Talassemie ed Emoglobinopatie
Collaborating Sponsors:
Associazione Italiana de Ematologia e Oncologia Pediatrica
Società Italiana di Medicina Trasfusionale e Immunoematologia
Conditions:
Anemia, Sickle Cell
Eligibility:
All Genders
Brief Summary
The "National Transfusion Treatment Survey in patients with sickle cell disease (SCD)" is a prospective longitudinal systemic study that was created in order to evaluate the therapeutic approach, main...
Detailed Description
Sickle Cell Disease (SCD) includes a group of rare inherited monogenic diseases caused by mutations of genes involved in hemoglobin biosynthesis and is characterized by the presence of a hemoglobin va...
Eligibility Criteria
Inclusion
- patients suffering of sickle cell disease, with diagnosis confirmed by standardized biochemical criteria or by matching mutations on globin genes by DNA analysis;
- all patients who consent to the study by signing the informed consent given by the U.O.C.
Exclusion
- patients without a diagnosis confirmed according to standardized biochemical criteria or via mutation on globin genes by DNA analysis.
- all patients unable to understand the study protocol and to give informed consent and who have no legal representative.
Key Trial Info
Start Date :
July 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03397017
Start Date
July 1 2016
End Date
June 30 2022
Last Update
April 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gian Luca Forni
Genova, Ge, Italy, 16121